Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa: is toxicity a myth?

Y Agid1

  • 1Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière, Paris, France.

Neurology
|May 5, 1998
PubMed
Summary
This summary is machine-generated.

Levodopa, a crucial Parkinson's disease treatment, is not neurotoxic. Studies show it does not cause irreversible nerve cell damage, only reversible side effects, when administered correctly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct prefrontal activations in processing sequence at the sentence and script level: an fMRI study.

Neuropsychologia·2000
Same author

Multiple origins of the spinocerebellar ataxia 7 (SCA7) mutation revealed by linkage disequilibrium studies with closely flanking markers, including an intragenic polymorphism (G3145TG/A3145TG).

European journal of human genetics : EJHG·1999
Same author

Levodopa in the treatment of Parkinson's disease: a consensus meeting.

Movement disorders : official journal of the Movement Disorder Society·1999
Same author

Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.

Neurology·1999
Same author

Dopaminergic cell group A8 in the monkey: anatomical organization and projections to the striatum.

The Journal of comparative neurology·1999
Same author

The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society·1999
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Area of Science:

  • Neuropharmacology
  • Neuroscience

Background:

  • Levodopa is a primary treatment for Parkinson's disease, necessitating an understanding of its long-term safety.
  • The definition of drug toxicity, particularly irreversible cell damage versus reversible side effects, is critical for evaluating levodopa's safety profile.

Purpose of the Study:

  • To critically evaluate the neurotoxicity of levodopa in the context of long-term Parkinson's disease treatment.
  • To differentiate between irreversible neurodegeneration and reversible side effects caused by levodopa.

Main Methods:

  • Review of in vivo and in vitro studies examining levodopa's effects on neuronal and glial cells.
  • Analysis of clinical data and experimental findings regarding levodopa's impact on cell function and survival.

Related Experiment Videos

Main Results:

  • Levodopa has not been demonstrated to accelerate neurodegeneration or cause permanent cell impairment in clinical or experimental settings.
  • In vitro levodopa toxicity at high concentrations or without glial cells does not directly translate to in vivo conditions due to protective cellular environments.
  • Observed side effects of levodopa are generally reversible and not indicative of permanent neuronal damage.

Conclusions:

  • Levodopa is not considered neurotoxic in vivo and does not cause irreversible nerve cell damage.
  • The primary concerns with levodopa therapy relate to manageable, reversible side effects, not inherent cellular toxicity.
  • When administered according to established therapeutic guidelines, levodopa is a safe and effective treatment for Parkinson's disease.